文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

白蛋白联合利尿剂治疗与脓毒症合并充血性心力衰竭患者死亡风险的相关性

[Correlation between albumin combined with diuretic therapy and mortality risk in septic patients with pre-existing congestive heart failure].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论在白蛋白基础上联用利尿剂,与脓毒症合并充血性心力衰竭患者ICU、30天和60天死亡风险降低相关(MIMIC-IV数据及外部验证结果一致)。

该回顾性队列研究基于MIMIC-IV 2.0数据库,纳入2008至2019年ICU收治的脓毒症合并充血性心力衰竭患者1754例(单用白蛋白组378例,白蛋白联合利尿剂组1376例),并在深圳市第二人民医院2022年10月至2023年12月收治的385例同类患者(单用白蛋白组144例,联合组241例)中进行外部验证。在校正人口学特征、合并症、实验室指标、病情严重程度和治疗措施后,多因素Cox回归显示联合治疗与ICU死亡风险降低(MIMIC-IV:HR=0.597,95%CI 0.460-0.774,P<0.001)和30天死亡风险降低(HR=0.557,95%CI 0.433-0.716,P<0.001)相关,外部验证结果一致。联合组60天累积生存率显著高于单用白蛋白组。结论认为白蛋白联合利尿剂治疗与脓毒症合并充血性心力衰竭患者死亡风险降低相关。

要点

  • 在MIMIC-IV队列中,联合组ICU死亡率为19.11%(263/1376),低于单用白蛋白组的30.42%(115/378),差异有统计学意义(P<0.05)。
  • 多因素Cox回归校正后,联合治疗与ICU死亡风险降低相关(HR=0.597,95%CI 0.460-0.774,P<0.001),与30天死亡风险降低相关(HR=0.557,95%CI 0.433-0.716,P<0.001)。
  • 外部验证队列385例中,联合组ICU死亡率为19.92%(48/241),低于单用白蛋白组的31.25%(45/144),差异有统计学意义(P<0.05)。
  • 亚组分析显示,无论性别、年龄及是否合并高血压、糖尿病、严重肝病、急性肾功能不全,也无论SOFA评分如何,联合治疗均与ICU死亡风险降低相关(所有HR<1,P<0.05),未见交互作用(所有P>0.05)。
  • Kaplan-Meier曲线显示,联合组60天累积生存率显著高于单用白蛋白组(Log-rank检验:χ²=49.62,P<0.05)。

适用人群与场景

  • MIMIC-IV 2.0数据库中2008至2019年ICU收治的脓毒症合并充血性心力衰竭患者。
  • 外部验证为深圳市第二人民医院2022年10月至2023年12月ICU收治的脓毒症合并充血性心力衰竭患者。

研究设计与关键结果

  • 研究类型为回顾性队列研究,MIMIC-IV队列纳入1754例(单用白蛋白组378例,白蛋白联合利尿剂组1376例),外部验证队列纳入385例(单用白蛋白组144例,联合组241例)。
  • MIMIC-IV队列主要终点ICU死亡率:联合组19.11%(263/1376) vs 单用白蛋白组30.42%(115/378),P<0.05;30天死亡率:联合组18.90%(260/1376) vs 单用白蛋白组32.54%(123/378),P<0.05;60天死亡率:联合组24.49%(337/1376) vs 单用白蛋白组39.15%(148/378),P<0.05。
  • MIMIC-IV队列多因素Cox回归校正人口学特征、合并症、实验室指标、病情严重程度和治疗措施后:ICU死亡风险HR=0.597(95%CI 0.460-0.774,P<0.001);30天死亡风险HR=0.557(95%CI 0.433-0.716,P<0.001)。
  • 亚组分析:无论性别、年龄及是否合并高血压、糖尿病、严重肝病、急性肾功能不全,也无论SOFA评分,联合治疗组ICU死亡风险均显著降低(所有HR<1,P<0.05),未见交互作用(所有P>0.05)。
  • Kaplan-Meier生存曲线:联合组60天累积生存率显著高于单用白蛋白组(Log-rank检验:χ²=49.62,P<0.05)。
  • 外部验证队列主要终点ICU死亡率:联合组19.92%(48/241) vs 单用白蛋白组31.25%(45/144),P<0.05;30天死亡率:联合组19.09%(46/241) vs 单用白蛋白组28.47%(41/144),P<0.05;60天死亡率:联合组24.07%(58/241) vs 单用白蛋白组34.03%(49/144),P<0.05;多因素Cox回归、亚组分析和Kaplan-Meier曲线结果与MIMIC-IV数据分析一致。

证据类型、等级与局限

  • 证据类型:回顾性队列研究,基于MIMIC-IV数据库分析并进行外部验证。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,白蛋白联合利尿剂治疗与脓毒症合并充血性心力衰竭患者死亡风险降低相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the correlation between albumin (Alb) combined with diuretic treatment and the mortality risk of septic patients with pre-existing congestive heart failure based on the United States Critical Care Medical Information Database-IV (MIMIC-IV), and to conduct the external validation.

METHODS: A retrospective cohort study was conducted. The clinical data of septic patients with pre-existing congestive heart failure admitted to the intensive care unit (ICU) from 2008 to 2019 in the MIMIC-IV 2.0 were extracted, including demographic characteristics, comorbidities, laboratory indicators on the first day of ICU admission, severity of illness, treatment measures, etc. For external validation, clinical data were collected from septic patients with pre-existing congestive heart failure admitted to the ICU of the Second People's Hospital of Shenzhen from October 2022 to December 2023. The patients were divided into Alb alone group and Alb combined with diuretic group. The ICU mortality was defined as the primary outcome event, and the 30-day and 60-day mortality were defined as the secondary outcomes. Multivariate Cox proportional hazard regression analysis was conducted to investigate the relationship between Alb combined with diuretic treatment and the mortality risk of ICU and 30 days in septic patients with pre-existing congestive heart failure, and subgroup analysis was performed. Kaplan-Meier survival curve was plotted to compared the 60-day cumulative survival rate between the Alb alone group and Alb combined with diuretic group.

RESULTS: (1) Analysis results of data from MIMIC-IV: a total 1 754 patients were enrolled, of which 378 in the Alb alone group, and 1 376 in the Alb combined with diuretic group. Compared with the Alb alone group, the patients in the Alb combined with diuretic group had significantly lower ICU, 30-day, and 60-day mortality [ICU mortality: 19.11% (263/1 376) vs. 30.42% (115/378), 30-day mortality: 18.90% (260/1 376) vs. 32.54% (123/378), 60-day mortality: 24.49% (337/1 376) vs. 39.15% (148/378), all P < 0.05]. Based on the multivariate Cox proportional hazard regression adjusted models considering demographic characteristics, comorbidities, laboratory indicators, severity of illness, and treatment measures, it was shown that the use of Alb combined with diuretic was significantly associated with a reduced risk death of ICU and 30 days [ICU mortality risk: hazard ratio (HR) = 0.597, 95% confidence interval (95%CI) was 0.460-0.774, P < 0.001; 30-day mortality risk: HR = 0.557, 95%CI was 0.433-0.716, P < 0.001]. Subgroup analysis revealed that after adjusting for variables, regardless of gender, age, and whether or not patients had comorbidities such as hypertension, diabetes, severe liver disease, acute renal insufficiency, and sequential organ failure assessment (SOFA) score, the ICU mortality risk was significantly reduced in patients treated with Alb combined with diuretic (all HR < 1, P < 0.05), with no interaction observed (all P > 0.05). Kaplan-Meier survival curve showed the 60-day cumulative survival rate of patients in the Alb combined with diuretic group was significantly higher than that in the Alb alone group (Log-rank test: χ 2 = 49.62, P < 0.05). (2) External validation: a total of 385 patients were enrolled, of which 144 in the Alb alone group, and 241 in the Alb combined with diuretic group. Compared with the Alb alone group, the patients of the Alb combined with diuretic group had significantly lower ICU, 30-day, and 60-day mortality [ICU mortality: 19.92% (48/241) vs. 31.25% (45/144), 30-day mortality: 19.09% (46/241) vs. 28.47% (41/144), 60-day mortality: 24.07% (58/241) vs. 34.03% (49/144), all P < 0.05]. The results of multivariate Cox proportional hazard regression analysis, subgroup analysis, and Kaplan-Meier survival curve analysis were consistent with the data analysis of the MIMIC-IV database.

CONCLUSIONS: Combination therapy of Alb and diuretic was associated with reduced mortality risk in septic patients with pre-existing congestive heart failure.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Huang Q, Zou Z, Lin Y, et al. [Correlation between albumin combined with diuretic therapy and mortality risk in septic patients with pre-existing congestive heart failure]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41331884. doi:10.3760/cma.j.cn121430-20240812-00693

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。